Acute diverticulitis of colon
Conditions
Interventions
daiobotanpito
placebo
Sponsors
Department of Japanese-Traditional (Kampo) Medicine, Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Moderate to severe diverticulitis Diagnosis will be based on computed tomography images: diverticula-like structure combined with tenderness or abdominal pain, a thickening of colon wall, signs of inflammation of pericolonic fat, tissue density, and vascular involvement. Pericolonic abscess, free air or extravasation, and accumulation of fluid will also be assessed to predict prognosis. 2. Age of at least 20 years and less than 75 years 3. Patients must be able to communicate with the investigators 4. Patients with abdominal pain and/or fever > 37.5 degree 5. After receiving sufficient explanation for participation in this study and achieving sufficient understanding, patients who provide written informed consent for participation.
Exclusion criteria
Exclusion criteria: 1. Patients with severe dysfunction in the following organs, based on blood tests within four weeks before treatment starts Renal function serum creatinine value 1.5-fold greater than the upper limit of the institutional standard Liver function serum AST value or serum ALT value 3-fold greater than the upper limit of the institutional standard Central nervous function encephalopathy or a patient suspected of it Electrolytes serum sodium less than 125, serum potassium less than 3.3 2. Patients considered highly likely to exhibit abscess perforation due to malnutrition, serum Albumin less than 2.5 3. Patients with symptoms of obstructive ileus 4. Patients who exhibit chronic anorexia, abdominal pain, and/or diarrhea symptoms before the onset of colorectal diverticulitis 5. Before the onset of colorectal diverticulitis, performance status, an indicator of general condition and the degree of restriction of the patient's daily life, of more than three 6. Patients who have a history of DBT administration 7. Patients undergoing treatment with insulin preparations 8. Immunocompromised patients 9. Pregnant women and those in the postpartum period 10. Patients with advanced allergy to Kampo formulas 11. Patients who the doctor considers to be inappropriate for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of fever-down (below 38 degrees) within 3 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization days Changes in inflammatory response Number of days before oral intake Recurrence rate Rate to loss abdominal pain within 4 days Types and frequencies of adverse events or side effects | — |
Countries
Japan
Contacts
Public ContactKeiko Ogawa
Kanazawa University Hospital Department of Japanese-Traditional (Kampo) medicine
Outcome results
None listed